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Abstract
Background: Anthroposophic medicine is a physician-provided complementary therapy system involving
counselling, artistic and physical therapies, and special medications. The purpose of this analysis was to identify
predictors of symptom improvement in patients receiving anthroposophic treatment for chronic diseases.
Methods: 913 adult outpatients from Germany participated in a prospective cohort study. Patients were starting
anthroposophic treatment for mental (30.4% of patients, n = 278/913), musculoskeletal (20.2%), neurological (7.6%),
genitourinary (7.4%) or respiratory disorders (7.2%) or other chronic indications. Stepwise multiple linear regression
analysis was performed with the improvement of Symptom Score (patients’ assessment, 0: not present, 10: worst
possible) after 6 and 12 months as dependent variables. 61 independent variables pertaining to socio-
demographics, life style, disease status, co-morbidity, health status (SF-36), depression, and therapy factors were
analysed.
Results: Compared to baseline, Symptom Score improved by average 2.53 points (95% confidence interval 2.39-
2.68, p < 0.001) after six months and by 2.49 points (2.32-2.65, p < 0.001) after 12 months. The strongest predictor
for improvement after six months was baseline Symptom Score, which alone accounted for 25% of the variance
(total model 32%). Improvement after six months was also positively predicted by better physical function, better
general health, shorter disease duration, higher education level, a diagnosis of respiratory disorders, and by a
higher therapy goal documented by the physician at baseline; and negatively predicted by the number of
physiotherapy sessions in the pre-study year and by a diagnosis of genitourinary disorders. Seven of these nine
variables (not the two diagnoses) also predicted improvement after 12 months. When repeating the 0-6 month
analysis on two random subsamples of the original sample, three variables (baseline Symptom Score, physical
function, general health) remained significant predictors in both analyses, and three further variables (education
level, respiratory disorders, therapy goal) were significant in one analysis.
Conclusion: In adult outpatients receiving anthroposophic treatment for chronic diseases, symptom improvement
after 6 and 12 months was predicted by baseline symptoms, health status, disease duration, education, and
therapy goal. Other variables were not associated with the outcome. This secondary predictor analysis of data from
a pre-post study does not allow for causal conclusions; the results are hypothesis generating and need verification
in subsequent studies.
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Chronic diseases are the most common cause of disease
burden worldwide and are rarely completely cured [1].
Strategies to improve the outcome of chronic diseases
include new drug regimens, enhanced healthcare provi-
sion, and patient self-management programs [2-4].
Many patients with chronic disease also use comple-
mentary therapies [5,6]. It is important to know which
types of patients will use complementary therapies and
which patients will profit from such use.
Anthroposophic medicine (AM), founded by Rudolf
Steiner and Ita Wegman [7], is a physician-provided
complementary therapy system. AM acknowledges a
spiritual-existential dimension in man, which is assumed to
interact with psychological and somatic levels in health and
disease. AM therapy for chronic disease aims to counteract
constitutional vulnerability, stimulate salutogenetic
self-healing capacities, and strengthen patient autonomy
[8-10]. This is sought to be achieved by counselling [9]; by
non-verbal artistic therapies using painting or clay [11,12],
music [13] or speech exercises [14]; by eurythmy movement
exercises [15]; by physical therapies [16,17]; and by special
AM medications. Worldwide, AM physicians work in 56
countries [18].
Patients using AM for chron i cd i s e a s ea r ep r e d o m i -
nantly women or children, education and occupation
levels are higher than average, and typical indications
are mental, respiratory, and musculoskeletal disorders
[9,10,19-21]. Studies of AM therapy for different cancers
[22-24] and facial neuralgia [25] have identified outcome
differences according to gender [23,25], psychosomatic
self-regulation [22], and performance status [24].
The Anthroposophic Medicine Outcomes Study
(AMOS) [20] provided an opportunity to assess a broad
range of outcome predictors in AM therapy users.
AMOS was a prospective, long-term cohort study of
patients starting AM therapies for various chronic dis-
eases. Following AM therapies, disease symptoms were
reduced and quality of life improved, without cost
increase [20,26]. Outcome differences have been
assessed in univariate analyses [27-39]. We present here
a multivariate analysis of predictors of symptom
improvement in adult patients of the AMOS study.
Methods
Design and objective
This was a secondary analysis of data from a prospective
observational cohort study conducted in German outpa-
tient settings. The study was initiated by a health insur-
ance company as part of a research program on the
effectiveness, costs, and safety of AM therapies in chronic
disease [20,26,40]. The purpose of the present analysis
was to identify variables predicting clinical improvement
following AM treatment for adults. For this purpose we
performed multiple linear regression analyses, with the
improvement of disease symptoms at 6- and 12-month
follow-up as dependent variables, and with various items
concerning disease status, socio-demographics, life-style,
and therapies as independent variables.
Setting, participants, and therapy
All physicians certified by the Physicians’ Association for
Anthroposophical Medicine in Germany and working in
an office-based practice or outpatient clinic in Germany
were invited to participate in the AMOS study. Certifica-
tion as an AM physician required a completed medical
degree and a three-year structured postgraduate training.
The participating physicians recruited consecutive patients
starting AM therapy. Patients enrolled in the period from
1 January 1999 to 31 December 2005 were included in the
present analysis if they fulfilled the following criteria:
1. Outpatients aged 17-75 years.
2. Starting AM therapy for any indication (main
diagnosis).
2A: AM-related consultation of at least 30 minutes
followed by new prescription of AM medication or
other AM treatment administered by the physician.
2B: or referral to AM treatment (art therapy, eur-
ythmy therapy or rhythmical massage therapy).
3. Duration of main diagnosis of at least 30 days at
study enrolment.
4. Symptom Score evaluable at baseline and at six-
month-follow-up.
Symptom Score was a compound measure of the
symptoms for which the patients had sought medical
attention. At baseline, the patients documented one to
six symptoms in order of decreasing importance and
assessed the intensity of each symptom on a numerical
rating scale from 0 ("not present”)t o1 0( " w o r s tp o s s i -
ble”) [41]. At each follow-up, the patients documented
the intensity of the same symptoms which they had
documented at baseline. Symptom Score was the aver-
age severity of all documented symptoms per patient at
each documentation point. This score has not been
validated.
Patients were excluded if they had previously received
the AM therapy in question (see inclusion criterion 2)
for their main diagnosis. For analysis of patients accord-
ing to AM therapy modality, patients fulfilling inclusion
criteria 2a as well as 2b were allocated to group 2b.
Variables
Dependent variable
Symptom Score was selected as dependent variable
because it directly described the severity of the symp-
toms for which the patients had sought help, and
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Symptom Score data were available after 3, 6, 12, 18
a n d2 4m o n t h s ;t h ec h a n g ef r o mb a s e l i n et o6 - m o n t h
follow-up was chosen for the main analysis because pre-
vious analyses [20,34-37] had shown that the AM thera-
pies were mainly administered in the first 3-6 months,
because most of the Symptom Score improvement
occurred during the first 6 months, and since follow-up
rates decreased progressively beyond 6 months.
Independent variables
Independent variables pertaining to socio-demographics,
life-style, disease status at baseline, and therapy factors
were selected from the dataset. Two types of variables
were selected. The first type were factors for which a
positive association with the outcome (e. g. better out-
come among patients with higher education) was a-
priori deemed to be possible:
￿ more favourable socio-demographic characteristics
and healthier life-style (e. g. higher education, not
smoking)
￿ more favourable health status at baseline (e. g. low
degree of comorbidity, short disease duration, low
depression scores)
￿ more experienced AM therapy providers (years
since qualifications of AM physicians and therapists,
respectively)
￿ previous treatment by the AM physician
￿ more intensive AM therapy (longer duration of
first consultation with AM physician, more AM
therapy sessions, more AM medications)
￿ more intensive non-AM therapy (e. g. more phy-
siotherapy sessions, more non-AM medications etc)
For the second type of variables there was no reason
to assume a priori a particular direction of an associa-
tion (e. g. no reason to assume that women have better
outcomes than men or vice versa):
￿ demographics (gender, age)
￿ baseline status (main diagnosis)
￿ treatment (primary care or other setting, main AM
therapy modality)
Since a large data set was available, and since the lit-
erature and clinical reasoning did not suggest otherwise,
the approach was deliberately broad, including as depen-
dent variables all variables of interest according to the
above criteria.
The original list of dependent variables had 47 items,
all of which were used in the final analyses. During revi-
sion of the analyses, the issue of selection bias was more
thoroughly investigated, prompting us to include one
further dependent variable: physician’st h e r a p yg o a lf o r
the patient at baseline. Thus a total of 48 items were
included (corresponding to 61 variables including
dummy variables, see Tables 1 and 2). Of these 48
items, 10 items (age, gender, diagnosis, disease duration,
depression, number of patients enrolled per physician,
main AM therapy modality, and the use of non-AM
medications, psychotherapy and physiotherapy, respec-
tively) had already been subject to bivariate analyses,
most of which had failed to show relevant associations
with clinical outcomes [28-39] (exceptions: different
results of AM medication therapy in diagnostic sub-
groups [38] and different results of asthma therapy in
adults vs. children [30]). The remaining 38 items were
selected without prior knowledge about bivariate asso-
ciations with outcome.
Data collection
All data were documented with questionnaires. Ques-
tionnaires used at study enrolment were handed out by
the physicians; follow-up questionnaires were adminis-
tered from the study office by post. All questionnaires
were returned in sealed envelopes to the study office.
The physicians documented eligibility criteria, diagnosis,
disease duration and severity, comorbid disorders, and
therapy goals; all other items were documented by the
patients. The patient responses were not made available
to the physicians. The physicians were compensated 40
Euro per included and fully documented patient, while
the patients received no compensation.
The data were entered twice by two different persons
into Microsoft® Access 97 (Microsoft Corp., Redmond,
WA, USA). The two datasets were compared and discre-
pancies resolved by checking with the original data.
Quality assurance, adherence to regulations
The study was approved by the Ethics Committee of the
Faculty of Medicine Charité, Humboldt University,
Berlin, Germany, and was conducted according to the
Declaration of Helsinki and largely following the ICH
Guideline for Good Clinical Practice E6. Written
informed consent was obtained from all patients before
enrolment.
Data analysis
The data analysis was performed on all patients fulfilling
the eligibility criteria, using PASW® Statistics 18.0 (SPSS
Inc., Chicago, Ill, USA) and StatXact® 5.0.3 (Cytel Soft-
ware Corporation, Cambridge, MA, USA).
Diagnoses were coded according to the International
Classification of Diseases, 10
th Revision. Medication use
was assessed as the number of patient-months of use.
For each medication, the number of patient-months was
calculated as ‘duration of use’ × ‘frequency of use’ (F),
where F = 1 for medication taken daily, 3-6 days per
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Variable N
evaluable
Mean Standard
deviation
Correlation
RP -
value
Age (years) 913 44.38 12.07 -0.08 0.020
Education level (1 = low, 2 = intermediate, 3 = high) 913 2.17 0.69 0.10 0.004
Net income per month (1-5
a) 733 3.86 1.10 0.05 0.151
Date of enrolment (0 = 1 Jan 1999, 7 = 1 Jan 2006) 913 2.35 1.82 0.03 0.341
AM medications in pre-study year (patient-months) 913 7.00 11.56 -0.03 0.335
Non-AM medications in pre-study year (patient-months) 913 10.91 14.89 -0.08 0.011
Psychotherapy in the pre-study year (sessions) 906 4.18 13.18 -0.01 0.809
Physiotherapy in the pre-study year (sessions) 913 8.73 17.96 -0.09 0.008
Disease duration (years) 913 7.84 9.23 -0.11 0.001
Disease severity at baseline (0-10) 902 6.68 1.74 0.10 0.004
Symptom Score at baseline (0-10) 913 6.01 1.77 0.47 < 0.001
Comorbid disorders (number) 913 1.76 1.34 -0.08 0.018
Chronic Disease Score (0-17 in this study) [65] 913 0.75 1.52 -0.08 0.014
SF-36 Physical Function Scale at baseline (0-100) [66] 909 75.46 23.35 0.04 0.240
SF-36 Role Physical Scale at baseline (0-100) 905 46.14 39.42 -0.06 0.071
SF-36 Role Emotional Scale at baseline (0-100) 900 50.19 41.64 -0.05 0.109
SF-36 Social Functioning Scale at baseline (0-100) 912 60.09 26.59 -0.09 0.008
SF-36 Bodily Pain Scale at baseline (0-100) 911 54.22 28.56 -0.05 0.129
SF-36 Vitality Scale at baseline (0-100) 910 38.55 18.81 -0.06 0.052
SF-36 Mental Health Scale at baseline (0-100) 910 54.21 19.37 -0.09 0.009
SF-36 General Health Scale at baseline (0-100) 902 50.65 19.34 0.00 0.917
SF-36 General Health Item at baseline (1 = excellent, 5 = poor) 908 3.58 0.77 -0.05 0.155
SF-36 Health Change Item at baseline
b 910 3.25 1.07 0.12 < 0.001
SF-36 Physical Component Summary at baseline 887 43.22 10.52 0.01 0.876
SF-36 Mental Component Summary at baseline 887 38.20 12.28 -0.07 0.029
Center for Epidemiological Studies Depression Scale, German version at baseline (0-60)
[67]
860 21.31 11.50 0.08 0.016
Physicians’ clinical experience (years since qualification) 124
c 18.20
c 7.44
c -0.01 0.748
Number of patients enrolled by the physician 124
c 7.36
c 10.69
c 0.06 0.073
Duration of consultation with physician at study enrolment (1-5
d) 913 1.87 1.06 -0.01 0.826
Physician’s therapy goal for the patient at study enrolment (1-6
e) 911 2.78 1.23 0.07 0.042
Therapists’ clinical experience (years since qualification) 123
e 12.04
e 7.23e 0.06 0.077
AM therapy in months 0-6 (therapy sessions) 905 8.79 8.71 0.06 0.062
AM medications in months 0-6 (patient-months) 911 6.57 7.83 -0.08 0.022
Non-AM medications in months 0-6 (patient-months) 911 6.33 8.22 -0.11 0.002
Psychotherapy in months 0-6 (therapy sessions) 906 2.51 7.67 -0.01 0.752
Physiotherapy in months 0-6 (therapy sessions) 909 3.91 9.74 -0.07 0.036
Correlation: Spearman-Rho correlation with dependent variable (Symptom Score difference 0-6 months).
aIncome: documented as 1 = < 500€,2=5 0 0 €-900€,3=9 0 0 €-1250€, 4 = 1250€-1750€, 5 = > 1750€.
bSF-36 Health Change Item: 1 = much better now than one year ago, 5 = much worse now than one year ago.
cNumbers refer to physicians not patients.
dDuration of consultation: documented as 1 = 0-29 min, 2 = 30-44 min, 3 = 45-59 min, 4 = ≥60 min.
d6 = cured, 5 = symptom free without ongoing therapy, 4 = symptom free with ongoing therapy, 3 = symptom improvement, 2 = avoidance of progression, 1 =
retardation of progression.
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taken 1-3 days per month; F = 0 for medication taken <
1 day per month. AM medications were defined as any
medication produced by Abnoba Arzneimittel GmbH,
Pforzheim, Germany; Helixor Heilmittel GmbH & Co,
Rosenfeld, Germany; WALA Heilmittel GmbH, Eckwäl-
den, Germany; or Weleda AG, Schwäbisch-Gmünd,
Germany. Non-AM medications were defined as all
other medications. The number of patient-months for
all AM medications and all non-AM medications,
respectively, was calculated as the sum of all patient-
months in question.
Bivariate analyses were performed using Fisher’s exact
test for independent binominal data, t-test for continu-
ous data, and Wilcoxon test for paired rank-ordered
data; median differences with 95% confidence intervals
(95%-CI) were estimated according to Hodges and Leh-
mann [42]. Bivariate correlations were calculated with
Spearman-Rho. All tests were two-tailed. Significance
criterion was p < 0.05. Since this was a descriptive
study, no adjustment for multiple bivariate comparisons
was performed [43].
For regression analysis, missing values were replaced
by the group mean value (except in a sensitivity analysis,
see below). Multinomial data were coded as dummy
variables. A total of 61 independent variables were ana-
lysed (Tables 1, 2). The possibility of clustered patient
sampling on the physician level was investigated by cal-
culating intraclass correlation coefficients (ICC type 1,1
according to Shrout and Fleiss [44]) between the depen-
dent variable (Symptom Score 0-6 month difference)
and physicians. There was no evidence of clustering:
(ICC = -0.51, p = 1.000). Likewise, there was no evi-
dence of clustering on the therapist level (ICC = -0.52,
p = 1.000). A multilevel analysis (physician and therapist
level in addition to patient level) was therefore not
Table 2 Binomial independent variables
Variable N N Correlation
Yes Evaluable R P-value
Female gender 748 913 -0.04 0.175
Wage earner 32 913 -0.03 0.424
Living alone 167 909 0.04 0.220
Alcohol use daily 26 913 -0.02 0.535
Smoking daily 102 912 -0.01 0.715
Overweight (Body mass index > 25) 234 899 0.03 0.339
Permanent work disability pension or severe disability status 168 911 -0.03 0.300
Main diagnosis (International Classification of Diseases, 10
th Revision)
￿ F00-F99 Mental/behavioural 278 913 0.02 0.584
￿ M00-M99 Musculoskeletal 184 913 -0.07 0.031
￿ G00-G99 Nervous system 69 913 0.03 0.365
￿ N00-N99 Genitourinary system 68 913 -0.04 0.267
￿ J00-J99 Respiratory system 66 913 0.08 0.019
￿ C00-D48 Neoplasms 56 913 0.05 0.104
￿ K00-K93 Digestive system 38 913 -0.01 0.691
￿ L00-L99 Skin and subcutaneous tissue 30 913 -0.03 0.419
￿ I00-I99 Circulatory system 29 913 -0.02 0.581
￿ E00-E90 Endocrine, nutritional, metabolic 25 913 -0.02 0.537
￿ Other diagnoses 70 913 0.01 0.732
Enrolment by primary care physician 757 913 -0.02 0.525
Previous treatment by physician 627 904 -0.03 0.391
Main AM therapy modality
￿ Eurythmy therapy 447 913 -0.04 0.200
￿ Art therapy 190 913 0.02 0.571
￿ Rhythmical massage therapy 90 913 0.02 0.549
￿ Medical therapy 186 913 0.02 0.564
Therapy costs reimbursed 554 913 -0.03 0.377
Correlation: Spearman-Rho correlation with dependent variable (Symptom Score difference 0-6 months). All variables were coded as 0: no, 1: yes.
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lysis was performed with estimation of variance compo-
nents by ordinary least squares. Criterion for inclusion
of variables in the model was p < 0.05 and for exclusion
p ≥ 0.10. Model assumptions were checked and verified
[45,46]. For all variables included in the model the var-
iance inflation factors were < 1.5, suggesting that multi-
collinearity was not a problem. Linearity, normality, and
homogeneity of variances were checked with graphical
methods. Cook’s distance was used to identify influential
observations, but no observations with significant influ-
ence were identified.
Five sensitivity analyses (SA) were performed to
explore whether altered preconditions lead to relevant
changes in the regression model:
￿ In SA1 missing values were not replaced, as in the
main analysis (n = 913); instead the sample was
restricted to patients with evaluable data for all 61
independent variables (n = 630).
￿ SA2 and SA3 were performed to validate the
model. While the main analysis comprised all eligi-
ble patients, in SA2 this analysis was repeated on a
random subsample of 75% of the original sample.
￿ SA3 was performed on the remaining 25% of the
original sample. The variables retained in the final
model of SA2 (a stepwise analysis), were forcibly
entered blockwise into a regression model.
￿ In SA4 and SA5 the dependent variable differed
from the main analysis and SA1-SA3 (the 0-6 month
improvement of Symptom S c o r e ,n=9 1 3 ) :I nS A 4
the dependent variable was instead the 0-12 month
improvement of Symptom Score (n = 840 evaluable
patients).
￿ In SA5 the dependent variable was the 0-6 month
improvement of the first ranked symptom of the 1-6
symptoms documented at baseline (instead of the
average of all symptoms per patients, i. e. Symptom
Score) (n = 906 evaluable patients). For this analysis,
t h eb a s e l i n es c o r eo ft h ef irst ranked symptom was
substituted for Symptom Score as independent
variable.
A few outliers with studentised residuals ≥ 3s t a n d a r d
deviations from zero were identified (main analysis, SA4
and SA5: each n = 1 outlier; SA1 and SA2: each n = 2
outliers). Outliers were retained in the main analysis
and in SA 5 for the following reasons: in the main ana-
lysis the exclusion of the outlier affected results only
minimally; in SA5 the exclusion of the outlier lead to
the introduction into the model of a predictor variable
(SF-36 role physical) which was not included in any
other model. Outliers were excluded in SA1, SA2 and
SA4 because in each case this exclusion lead to the
disappearance from the model of a predictor variable
not included in any other model (SA4: living alone) or
not included in any other model but SA1 and SA2 (SA1
and SA2: enrolment by primary care physician).
Results
Patient enrolment
From 1 January 1999 to 31 December 2005, a total of
1,176 patients aged 17-75 years were assessed for eligibil-
ity. Of these patients, 913 fulfilled all eligibility criteria and
were included in the analysis. Of the 263 patients who
were not included, 156 did not have Symptom Score eva-
luable at 0 and 6 months and 107 patients were not
included in the AMOS study for the following reasons:
patients’ baseline questionnaire missing (n = 42), patients’
and physicians’ baseline questionnaire dated > 30 days
apart (n = 36), previous or ongoing use of AM therapy (n
= 15), no informed consent (n = 9), other reasons (n = 5).
Included (n = 913) and not included patients (n = 263) did
not differ significantly regarding age, gender, diagnosis,
disease duration, baseline disease severity or baseline
Symptom Score.
A total of 124 physicians enrolled patients. These phy-
sicians did not differ significantly from eligible physicians
without study patients (n = 215, excluding paediatricians)
regarding the number of years in practice (mean ± stan-
dard deviation 18.2 ± 7.4 years vs. 20.1 ± 9.7 years, p =
0.087) and the proportion of primary care physicians
(84.7% vs. 82.3%, p = 1.000). Significant differences were
found regarding age (46.9 ± 7.1 years vs. 49.0 ± 8.3 years,
p = 0.027, mean difference 2.1 years, 95% confidence
interval [95%-CI] 0.2-3.9 years) and the proportion of
male physicians (53.2% vs. 64.7%, p = 0.0497, odds ratio
for male gender 1.61, 95%-CI 1.03-2.52).
The patients referred to AM art, eurythmy or rhythmi-
cal massage therapy were treated by 203 different thera-
pists. Comparing these therapists to eligible therapists
without study patients (n = 972), no significant differ-
ences were found regarding age (mean 48.9 ± 7.8 vs. 50.5
± 9.8 years, p = 0.078), gender (83.3% vs. 80.7% women, p
= 0.431) or the number of years since therapy school gra-
duation (12.0 ± 7.2 vs. 13.3 ± 9.0 years, p = 0.144).
Each physician enrolled 1-4 patients (59.7%, n = 74/
124 physicians), 5-9 patients (19.4%, n = 24) or ≥ 10
patients (21.0%, n = 26), with a median of 3.0 patients
enrolled per physician (range 1-55 patients, interquartile
range 2.0-8.0 patients, average 7.4 patients). For the
whole AMOS sample enrolled in the same period (n =
1,568 children and adults) the corresponding number
was average 10.2 patients enrolled per physician.
Correlates of patient selection
For patients referred to new AM treatment with eur-
ythmy, art or rhythmical massage therapy (see Methods,
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investigated if the degree of patient selection by the phy-
sicians correlated with the physicians’ therapy goal for
the patient at study enrolment or with the Symptom
Score 0-6 month difference. The degree of patient selec-
tion by the physicians was estimated for the whole
AMOS study as follows:
￿ The patient recruitment into AMOS lasted from 1
July 1998 to 31 December 2005 (a total of 2,741
days). For each physician enrolling patients at least
once in this period (n = 155 physicians), the physi-
cian’s recruitment period was calculated as the num-
ber of days between the first and last enrolled
patient. For physicians enrolling patients on more
than one day (n = 130 physicians) the average
recruitment period was 817 days, corresponding to
30.0% of the total recruitment period of 2741 days.
￿ In a survey of AMOS physicians conducted in
November 2001, the physicians retrospectively docu-
mented the number of patients they had referred to
new AM treatment in the past 12 months (corre-
sponding to inclusion criterion 2B of the present
analysis).
￿ For each physician with available data from this
survey and enrolling patients on more than one day
(n = 66 physicians), the degree of selection was cal-
culated as the ratio (number of patients enrolled
into AMOS and referred to new AM treatment in
the physician’s recruitment period)/(number of
patients referred to new AM treatment according to
the survey). The ratio was adjusted to a 12-month
period. For the whole AMOS study it was thus esti-
mated that the physicians enrolled 30.7% of the
patients they referred to new AM treatment.
Of the 124 physicians enrolling patients into the pre-
sent sample, 109 physicians enrolled patients referred to
new AM treatment (n = 727 patients). Of these 109
physicians, 102 physicians enrolled patients on more
than one day (with n = 720 patients referred to AM
treatment), and 56 physicians (with n = 500 patients
referred to AM treatment) also had available data on
the degree of patient selection. For these 500 patients,
the degree of patient selection of their physician was
analysed for correlations: The degree of patient selection
was significantly correlated with the physicians’ therapy
goal at baseline (Spearman-Rho = 0.12; p = 0.008) but
not with the Symptom Score 0-6 month difference
(Spearman-Rho = 0.01; p = 0.744).
Patient description
The patients were recruited from 15 of 16 German fed-
eral states. Age groups were 17-29 years (9.2%, 84 of
913 patients), 30-39 years (26.9%), 40-49 years (34.8%),
50-59 years (15.3%), and 60-75 years (13.7%) with a
mean age of 44.4 ± 12.1 years. A total of 81.9% (748/
913) of the patients were women.
Most frequent main diagnoses were mental disorders
(30.4%, 278 of 913 patients) and musculoskeletal dis-
eases (20.1%) (Table 2). Further data on demographics,
morbidity, and therapies are presented in Tables 1 and
2. Of the 1-6 symptoms documented per patient (see
Methods), the first ranked symptom (mean 6.37 points
at baseline) had a higher intensity than the remaining
five symptoms (range of means 5.43 to 5.96 points, aver-
age of means 5.72 points) (p < 0.001). Likewise the 0-6
month improvement of the first ranked symptom (aver-
age 2.84 points, 95%-CI 2.67-3.02 points) was more pro-
nounced than the improvement of the remaining
symptoms (2.17 points, 95%-CI 1.99-2.34 points) (p <
0.001).
Symptom Score averaged 6.01 ± 1.77 points at base-
line and improved by average 2.53 points (95%-CI 2.39-
2.68 points, p < 0.001, n = 913) from 0 to 6 months, by
2.49 points (95%-CI 2.32-2.65 points, p < 0.001, n = 840
evaluable patients) from 0 to 12 months, and by 2.73
points (95%-CI 2.55-2.91 points, p < 0.001, n = 793)
from 0 to 24 months.
At 6-month follow-up the physicians documented the
highest therapy goal attained (rank ordered scale: see
Methods section, with the additional response category
“no goal attained”). Compared to the goal formulated by
the physician at enrolment, a higher goal was attained
in 13.6% of patients (n = 104 of 761 patients with physi-
cian follow-up data available), the same goal was
attained in 44.7% (n = 340), and a lower goal or no goal
was attained in 41.7% (n = 317); the Hodges-Lehmann
estimate of median difference indicated that a 1.00 point
lower goal was attained at follow-up compared to the
goal aimed for at baseline (95%-CI 1.00-1.50 points;
Wilcoxon signed-rank test: p < 0.001).
Predictors of 0-6 month Symptom Score improvement
Variable not included in main analysis
One item of potential interest, ‘duration of physician-
patient-relationship’ (i. e. how many years has the
patient been treated by the study physician) was not
included in the main analysis, since this item was only
documented in a subset of patients enrolled after 15
May 2002 (n = 175). In these patients the duration of
the physician-patient-relationship showed only a weak
and non-significant correlation with the 0-6 month
Symptom Score improvement (Spearman-Rho = -0.05,
p = 0.524).
Main analysis
Of 61 analysed independent variables, 19 variables
showed significant univariate correlations (p < 0.05)
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Page 7 of 14with the 0-6 month Symptom Score improvement, but
only four of these variables had correlations with Spear-
man-Rho > ± 0.10 (baseline Symptom Score: r = 0.47;
baseline SF-36 Health Change item: r = 0.12; disease
duration: r = -0.11; use of non-AM medications in
months 0-6: r = -0.11) (Tables 1, 2).
Stepwise multiple linear regression analysis yielded a
significant model (F = 49,397; p < 0.001) which
accounted for 32% of the variance (Tables 3) and
included nine predictor variables. The strongest predic-
tor was baseline Symptom Score, which alone accounted
for 25% of the variance. The regression coefficients of
the model (Tables 3, 4) can be clinically interpreted as
follows (each interpretation presupposes that all other
variables in the model are kept constant):
1. Symptom Score at baseline: For each 1.00 point
increase in baseline Symptom Score (increase means
worse symptoms) the 0-6 month Symptom Score
improvement will increase by average 0.74 points
(95%-CI 0.66-0.81).
2. SF-36 Physical Function at baseline:For each 1
point increase in the baseline SF-36 Physical Func-
tion Scale (increase means better physical function)
the improvement will increase by average 0.01
points. E. g. in patients with an increase of 20 points
(approximately one-half standard deviation of this
scale) the Symptom Score improvement will increase
by 0.20 points.
3. Education level: Patients with high education level
will have average 0.31 points (95%-CI 0.14-0.49) lar-
ger improvement than patients with intermediate
education level, and these will have 0.31 points lar-
ger improvement than patients with low education
level.
4. SF-36 General Health at baseline: For each 1 point
decrease in the baseline SF-36 General Health item
(decrease means better general health) the improve-
ment will increase by average 0.29 points (95%-CI
0.11-0.47).
5. Main diagnosis J00-J99 Respiratory System:
Patients with this diagnosis will have average 0.77
points (95%-CI 0.29-1.25) more improvement than
all other patients.
6. Disease duration: For each year of disease dura-
tion prior to study enrolment, the improvement will
decrease by 0.02 points (95%-CI 0.01-0.03).
7. Main diagnosis N00-N99 Genitourinary System:
Patients with this diagnosis will have average 0.63
points (95%-CI 0.16-1.10) less improvement than all
other patients.
8. Physiotherapy in the pre-study year: For each phy-
siotherapy session in the pre-study year the improve-
ment will decrease by average 0.01 points (95%-CI
0.00-0.02). E. g. patients with 12 physiotherapy ses-
sions will have 0.12 points less improvement than
patients without physiotherapy.
9. Physicians’ therapy goal at baseline: For each
higher step on the rank-ordered scale of therapy
goals (see Methods for details) the improvement will
increase by 0.12 points (95%-CI 0.02-0.22).
Sensitivity analyses
Five sensitivity analyses (SA) were performed (see Meth-
ods for details). All SA yielded significant models with
7-11 independent variables, together accounting for
31%-33% of the variance (Tables 4 and 5). Of the nine
variables in the main model, three variables remained
significant predictors in all five SA (baseline Symptom
Score [in SA5: first ranked symptom at baseline], base-
line SF-36 Physical Function, baseline SF-36 General
Health), two variables remained significant predictors in
four SA (education level, physician’st h e r a p yg o a la t
baseline: SA1+2+4+5), and one variable remained a sig-
nificant predictor in three SA (respiratory disorders:
Table 3 Predictors of 0-6 month Symptom Score improvement: results of stepwise multiple regression analysis
Variable R Adjusted
R
2
B Standard error of
B
Beta t-
value
P-
value
Intercept -1.87 0.69 -2.73 0.007
1. Symptom Score at baseline (1-10) 0.50 0.25 0.74 0.04 0.58 20.16 < 0.001
2. SF-36 Physical Function Scale at baseline (0-100) 0.53 0.28 0.01 0.00 0.11 3.36 0.001
3. Education level (1 = low, 2 = intermediate, 3 = high) 0.54 0.29 0.31 0.09 0.10 3.46 0.001
4. SF-36 General Health Item at baseline (1-5) 0.55 0.30 -0.29 0.09 -0.10 -3.17 0.002
5. Main diagnosis J00-J99 Respiratory system (0: no, 1: yes) 0.56 0.31 0.77 0.24 0.09 3.14 0.002
6. Disease duration (years) 0.56 0.31 -0.02 0.01 -0.08 -2.70 0.007
7. Main diagnosis N00-N99 Genitourinary system (0: no, 1: yes) 0.57 0.32 -0.63 0.24 -0.07 -2.65 0.008
8. Physiotherapy in pre-study year (sessions) 0.57 0.32 -0.01 0.00 -0.07 -2.54 0.011
9. Physician’s therapy goal at baseline (6 = cured, 1 = retardation of
progression)
0.57 0.32 0.12 0.05 0.06 2.26 0.024
R: Multiple correlation coefficient. Adjusted R
2: Adjusted coefficient of multiple determination. B: Regression coefficient. Beta: Standardised regression coefficient.
Hamre et al. BMC Research Notes 2010, 3:218
http://www.biomedcentral.com/1756-0500/3/218
Page 8 of 14SA1+2+5). Seven of the nine variables in the main
model (not the two diagnoses) also predicted Symptom
Score improvement after 12 months (SA4), and eight
variables (not disease duration at baseline) also pre-
dicted the improvement of the first ranked baseline
symptom after 6 months (SA5).
Among the SA using the improvement of Symptom
Score as dependent variable (SA1-4), all had baseline
Symptom Score as first ranked variable in the model
(not applicable for SA3, where all variables were
included blockwise), this variable alone accounting for
23%-27% of the variance. The regression coefficient for
baseline Symptom Score (main analysis: 0.74 point more
improvement per 1.00 point increase in baseline Symp-
tom Score) showed very little variation in SA1-4 (range
0.72-0.75 points). In SA5 the first ranked symptom had
been substituted for Symptom Score as independent
(baseline score) and dependent variable (0-6 month
change); results were very similar to the other analyses,
with the first symptom being first ranked variable in the
model, accounting for 23% of the variance, and with a
similar regression coefficient of 0.72.
Table 4 Sensitivity analyses (SA): Regression coefficients with 95% confidence intervals
Variable Main
analysis
SA1: Evaluable
data for all
variables
SA2: 75%
subsample
SA3: Remaining 25%,
variables from SA2
SA4: 0-12
month
improvement
SA5: Dependent
variable First
Symptom
1. Symptom Score at baseline
(0-10)*
0.74 (0.66
to 0.81)
0.75 (0.66 to 0.83) 0.73 (0.65
to 0.81)
0.74 (0.59 to 0.90) 0.75 (0.67 to 0.83) 0.72 (0.64 to 0.79)
2. SF-36 Physical Function
Scale at baseline (0-100)
0.01 (0.004
to 0.02)
0.01 (0.01 to 0.02) 0.01 (0.003
to 0.02)
0.01 (0.002 to 0.03) 0.01 (0.002 to
0.02)
0.01 (0.0003 to 0.02)
3. Education level (1-3) 0.31 (0.14
to 0.49)
0.32 (0.10 to 0.54) 0.35 (0.15
to 0.56)
0.31 (-0.06 to 0.69) 0.30 (0.11 to 0.50) 0.44 (0.22 to 0.66)
4. SF-36 General Health Item
at enrolment (1-5)
-0.29 (-0.47
to -0.11
-0.26 (-0.48 to -0.05) -0.23 (-0.43
to -0.03)
-0.63 (-1.03 to -0.23) -0.24 (-0.44 to
-0.05)
-0.23 (-0.44 to -0.01)
5. Main diagnosis J00-J99
Respiratory system**
0.77 (0.29
to 1.25)
0.68 (0.13 to 1.23) 0.76 (0.24
to 1.27)
0.65 (-0.46 to 1.77) — 0.67 (0.10 to 1.25)
6. Disease duration (years) -0.02 (-0.03
to -0.01)
-0.02 (-0.03 to
-0.0005)
—— -0.02 (-0.03 to
-0.002)
—
7. Main diagnosis N00-N99
Genitourinary system**
-0.63 (-1.10
to -0.16)
-0.62 (-1.18 to -0.07) —— — -0.72 (-1.28 to -0.16)
8. Physiotherapy in pre-study
year (sessions)
-0.01 (-0.02
to -0.002)
—— — -0.01 (-0.02 to
-0.01)
-0.01 (-0.02 to -0.004)
9. Physician’s therapy goal at
baseline (1-6)
0.12 (0.02
to 0.22)
0.18 (0.06 to 0.30) 0.17 (0.06
to 0.28)
0.01 (-0.22 to 0.23) 0.18 (0.07 to 0.29) 0.27 (0.15 to 0.40)
10. Psychotherapy in pre-
study year (sessions)
— -0.01 (-0.02 to
-0.004)
—— — —
11. Wage earner** —— 0.90 (0.18
to 1.62)
-0.66 (-2.28 to 0.97) — 1.04 (0.24 to 1.84)
12. Non-AM medications in
month 0-6 (patient-months)
——— — -0.03 (-0.05 to
-0.01)
-0.02 (-0.04 to -0.002)
13. Main diagnosis C00-D48
Neoplasms**
——— — — 0.70 (0.08 to 1.32)
*SA5: First ranked symptom at enrolment. **: 0: no, 1: yes. —: Variable not included in the model.
Table 5 Sensitivity analyses (SA): Summary of models
Analysis N patients Included variables Adjusted R
2
1
st variable
Adjusted R
2
Full model
ANOVA
P-Value
Main analysis 913 1,2,3,4,5,6,7,8,9 0.25 0.32 < 0.001
SA1: Patients with evaluable data for all variables 630 1,2,9,3,10,4,5,7,6 0.24 0.33 < 0.001
SA2: 75% random subsample 698 1,2,5,3,9,11,4 0.27 0.33 < 0.001
SA3: Remaining 25%, variables from SA2 model 213 1+2+5+3+9+11+4 Not applicable 0.32 < 0.001
SA4: Dependent variable Symptom Score 0-12 months 839 1,2,12,8,9,3,4,6 0.23 0.33 < 0.001
SA5: Dependent variable First Symptom 0-6 months 906 1*,2,9,3,8,7,11,4,5,13,12 0.23* 0.31 < 0.001
Included variables: Variable numbers from Table 4. *: Variable 1 = First ranked symptom at enrolment. Adjusted R
2: Adjusted coefficient of multiple
determination. ANOVA p-value: Analysis of variance with significance test for total model.
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ranked variable (again not applicable for SA3) with a
regression coefficient of 0.01 in all analyses.
The regression coefficients for the other predictor
which was significant in all SA (baseline SF-36 General
Health) also varied relatively little in SA1+2 and SA4+5
but showed more variation in SA3 (Table 4).
In all SA one variable (SA1-4) or three independent
variables (SA5) which had not been included in the
main model were now included, altogether four new
independent variables (Table 4):
￿ In SA1 psychotherapy in the pre-study year was a
negative predictor.
￿ In SA2 and SA5 the variable ‘wage earner’ was a
positive predictor. However, in SA3 this prediction
was reversed and no longer significant.
￿ I nS A 4a n dS A 5t h eu s eo fn o n - A Mm e d i c a t i o n s
in months 0-6 was a negative predictor.
￿ In SA5 a main diagnosis of neoplasms was a posi-
tive predictor.
￿ If outliers were retained in SA1 and SA 2 (see
Methods for details) enrolment by primary care phy-
sician was a positive predictor in these two SA.
Results (not shown elsewhere) indicate that patients
enrolled in primary care will have 0.40 point more
improvement than patients enrolled in specialist
practice or outpatient clinics.
Discussion
Major findings
This is the first multivariate predictor analysis of long-
term outcome following AM treatment for chronic non-
cancer indications in adults. In 913 adult outpatients in
Germany, improvement after 6 and 12 months was posi-
tively predicted by higher baseline symptom severity,
better physical function, better general health, and (in
most analyses) higher education level and a higher ther-
apy goal at baseline. The remaining variables were not
significant predictors or were not retained when repeat-
ing the analysis on random subsamples of the original
sample. Baseline symptom severity was the strongest
predictor, accounting for 25% of the variance (total
model 32%).
Strengths and limitations
Strengths of this analysis include a large sample size,
validation of the main model in subsamples, and a high
representativeness due to the participation of 22% of eli-
gible AM physicians and therapists in Germany. The
participating AM physicians and therapists resembled
eligible but not participating physicians and therapists
with respect to demographic characteristics, and the
included patients resembled not included patients
regarding baseline characteristics [20]. These features
suggest that the study mirrors contemporary AM use in
outpatient settings to a high degree. The analysis also
comprised a detailed assessment of socio-demographics,
disease status, co-morbidity, disability, depression,
AM therapies, adjunctive therapies, and therapist
factors. Other factors of potential interest, such as psy-
chosomatic [22] or autonomic [47] self-regulation,
patient expectations [48,49], and perceived quality of the
physician-patient relationship and therapist-patient rela-
tionship could not be assessed, as they were not docu-
mented in the study.
Since the study had a long recruitment period, the
study physicians were not able to screen and enrol all
eligible patients (criteria: see Methods section). For
patients referred to new AM therapies, it was estimated
that physicians enrolled 31% of eligible patient into
AMOS. This selection could bias results if physicians
were able to predict therapy response and if they prefer-
entially screened and enrolled such patients for whom
they expected a particularly favourable outcome. The
available data suggest that the physicians may to some
degree have selected patients with an expected positive
outcome: the degree of patient selection (= the propor-
tion of eligible vs. enrolled patients) showed a significant
albeit weak correlation (Spearman-Rho 0.12) with physi-
cians’ therapy goal at baseline. However, the physicians’
ability to predict future outcomes was far from perfect:
their therapy goals were not attained in 42% of patients,
and therapy goals at baseline showed only a weak corre-
lation with the Symptom Score improvement at 6-
month follow-up (Spearman-Rho 0.07). Moreover, the
degree of patient selection in itself was not correlated
with the Symptom Score improvement. Thus, if any
patient selection on account of expected therapy
response did occur, the analysed data do not suggest
that such a selection affected clinical outcomes. Notably,
our analysis of patient selection has several limitations:
it did not include patients starting AM medical therapy
(inclusion criterion 2A, see Methods: 20% of the present
sample); the analysis was based on a retrospective docu-
mentation of the number of eligible patients; and,
because of non-response and other reasons, 31% of
patients referred to new AM therapy had no available
data on the degree of selection. We cannot, therefore,
exclude an effect of patient selection on the predictions
found in the present analysis.
The target of the present predictor analysis was pre-
post improvement after 6 and 12 months in patients
receiving AM therapy for chronic disease. Long-term
improvement is a useful outcome measure in rehabilita-
tion research, but pre-post improvement may of course
have other causes apart from the therapy. Since the pre-
sent analysis was based on data from a single-arm study
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estimated through direct comparison to a control group.
The independent variable used in the main analysis of
this paper, Symptom Score, is a compound score of the
1-6 most relevant symptoms in each patient, measured
on 0-10 point numerical rating scales. Numerical rating
scales are valid, reliable and responsive measures of pain
[41], and 0-10 point numerical rating scales have been
extensively used to measure other symptoms than pain
[50-53] as well as global disease severity [54]. In addi-
tion, compound scores, based on several 0-10 point
numerical rating scales, have been constructed to mea-
sure individualised qualityo fl i f e[ 5 5 ] .T h ec o m p o u n d
Symptom Score used in this study has not been vali-
dated. However, when Symptom Score was substituted
with the single most important baseline symptom in
each patient, measured on a single numerical rating
scale (SA5), results were very similar to the main
analysis.
Our regression models are of course, like all statistical
models, imperfect representations of reality [56]; they do
not prove causality, and residual confounding cannot be
ruled out. A limitation of stepwise multiple linear
regression analyses on a large dataset using a large num-
ber of independent variables is the possibility of chance
findings from modelling random variations [57].
Another limitation of the present analysis is that it was
not pre-specified in the original protocol. Altogether,
this secondary predictor analysis of data from a pre-post
study does not allow for causal conclusions; the results
are hypothesis generating and need verification in subse-
quent studies.
Interpretation, comparison to other studies
The strongest outcome predictor in this analysis was
baseline symptoms. The more outspoken improvement
among patients with worse baseline symptoms can have
several causes, such as more room for improvement and
more regression to the mean with higher score values,
the hello-goodbye effect, and a higher patient motivation
with therapies working better at higher symptom levels
[39,58]. Physical function as well as general health at
baseline predicted future improvement in the opposite
direction than baseline symptoms (i. e. better physical
function and better general health predicted more
improvement while lower symptom intensity predicted
less improvement). These findings are plausible, since
AM aims to mobilise self-healing capacities [9,10] and
since patients with better physical fitness and/or general
health may have more such capacities than patients with
poor fitness and health, independently of symptom
severity. Good general health and fitness might thus
enhance natural as well as therapy-induced recovery.
A higher education level was a significant positive
predictor of improvement in the main analysis and in
four out of five sensitivity analyses. Well educated
patients may have more motivation or capacity to
engage in artistic (eurythmy exercises, art therapy) and
self-reflective therapy forms (AM consultations). How-
ever, the 150 patients with low education levels in this
analysis also had a significant and clinically relevant
improvement of average 2.05 points.
The physicians’ therapy goal for the patients at base-
line was also a significant positive outcome predictor in
five out of six analyses. Therapy goals may reflect physi-
cians’ prognostic assessment of patients’ future therapy
response, as discussed above. In this respect, physicians’
observation of patients may yield prognostic information
in addition to the information provided by the other
predictors in our analysis. In addition, higher therapy
goals may reflect the physicians’ healing intentions [8,9]
and a general therapeutic optimism.
The patients in this analysis were treated for a range
of diagnoses. Among the ten most common diagnosis
groups the only clearly significant outcome difference
was a more outspoken 0-6 month improvement in
patients with respiratory disorders (n = 66 patients,
thereof 36 patients with asthma). Notably, a respiratory
disorder was no significant predictor of improvement in
the 25% subsample (SA3) and after 12 months (SA4).
On the other hand, the point estimate for the regression
coefficient in SA3 (0.65 points more improvement in
patients with respiratory disorder than in other patients)
was similar to the estimates in the main analysis and
SA1-2 (range 0.67-0.77). When comparing different
diagnoses one should take into account that symptom
improvement, although documented uniformly with
Symptom Score in all patients, may still have different
meanings in different diagnosis groups. Predictor ana-
lyses restricted to individual diagnosis groups might of
course yield results differing from the present analysis.
Negative predictions were found for increasing disease
duration, genitourinary disorders, and physiotherapy in
the pre-study year. These predictions should be inter-
preted with considerable reserve, since each of them
was only reproduced in two out of five sensitivity ana-
lyses. The negative prediction by physiotherapy was con-
trary to our a-priori assumptions and may suggest that
physiotherapy is an independent marker of chronicity
and therapy refractoriness, rather than being harmful in
itself. Other variables (psychotherapy in pre-study year,
non-AM medication use in month 0-6, wage earner,
neoplasm as main diagnosis) were only significant pre-
dictors in 1-2 sensitivity analysis and not in the main
analysis and should therefore be interpreted with
extreme caution.
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Page 11 of 14Apart from the AMOS study, two other studies have
investigated associations between patient characteristics
and outcome of comprehensive AM treatment for chronic
disease in adults [24,59]: In a study of inpatient AM treat-
ment for patients with advanced epithelial cancer,
improvements in quality of life were found among patients
with good and bad performance status, respectively, but
the two groups showed improvements in different quality
of life domains [24]. In a Swiss study of adult primary care
patients starting AM treatment for various disorders
(thereof 53% with disease duration > 3 months), patient
satisfaction and perceived benefit at four-week follow-up
were independent of age and gender [59]. The latter find-
ing was confirmed in our analysis of a German predomi-
nantly primary care sample. The predictions of
improvement by higher baseline symptoms and shorter
disease duration in this analysis of adult AMOS patients
were also found in a corresponding predictor analysis of
children in the AMOS study [27]. These two multivariate
analysis also confirm previous univariate analyses from the
AMOS study, showing similar improvement among differ-
ent AM therapy modality groups [20,34-37]. This finding
may be due to a predominant effect common to all AM
therapy modalities. The opposite is also possible; different
therapy modalities may have specific effects and still work
comparably well for the respective patient groups.
Some of the significant outcome predictors in this analy-
sis of AM treatment have also been identified as significant
predictors of outcome following other complementary
therapies for chronic conditions: baseline symptom inten-
sity [48,60-63], disease duration [62], education [60,61],
and baseline SF-36 scores [48,60,61]. However, education
was not a significant outcome predictor in other studies of
complementary therapies [49,64].
Regarding the SF-36 Health Survey, we analysed all
eight SF-36 scales, the two SF-36 summary scores, and
two further SF-36 items as independent variables,
whereby the Physical Function scale and the General
Health item were significant predictors. Several outcome
prediction analyses of other complementary therapies
have included one or both SF-36 summary scores but
none of the remaining SF-36 scales or items as indepen-
dent variables [48,60,61]. In these analyses, baseline SF-
36 Physical Component Summary score [48,60,61] and
baseline SF-36 Mental component summary score
[60,61] were significant positive predictors of intermedi-
ate outcomes (discharge from inpatient rehabilitation
[48] and three-month follow up [60,61], respectively).
When the present analysis was repeated, retaining the
two SF-36 summary scores but excluding the remaining
SF-36 scales and SF-36 items from the independent vari-
ables, both the SF-36 Physical and Mental Component
Summary scores emerged as significant positive predic-
tors for the 0-6 month Symptom Score improvement.
Some studies of other complementary therapies have
identified further outcome predictors which were not
significant predictors in the present study: age
[60,61,64], gender [60,61], and the number of therapy
sessions [48]. However, in other studies of complemen-
tary therapies, age [49] and gender [49,64] were not sig-
nificant predictors, like in the present study.
Conclusions
This is the first multivariate predictor analysis of long-
term outcome following AM treatment for chronic non-
cancer indications in adult outpatients. Symptom
improvement after 6 and 12 months was positively pre-
dicted by higher baseline symptom severity, better physi-
cal function, better general health, and in most analyses
a higher education level and a higher therapy goal at
baseline. A number of other variables were not asso-
ciated with the outcome. This secondary predictor ana-
lysis of data from a pre-post study does not allow for
causal conclusions; the results are hypothesis generating
and need verification in subsequent studies.
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